| Description |
QN523 is a novel scaffold with drug-like properties, showing potent in vitro cytotoxicity in a panel of 12 cancer cell lines. QN523 induces apoptosis and autophagy. QN523 can be used in research of cancer[1].
|
| Related Catalog |
|
| In Vitro |
QN523 (72 h) has cytotoxicity with IC50 values ranging from 0.1 to 5.7 μM across 12 cell lines[1]. QN523 (0.1 and 0.5 μM; 24 and 48 h; MIA PaCa-2 cells) arrests cell cycle at S phase and delays for pancreatic cancer cells to enter the G2-M phase. QN523 induces apoptosis and autophagy of MIA PaCa-2 Cells[1]. Cell Cycle Analysis[1] Cell Line: MIA PaCa-2 cells Concentration: 0.1 and 0.5 μM Incubation Time: 24 and 48 hours Result: Delayed for pancreatic cancer cells to enter the G2-M phase because of accumulation of cells in the S phase. Apoptosis Analysis[1] Cell Line: MIA PaCa-2 cells Concentration: 0.1 and 0.5 μM Incubation Time: 24 and 48 hours Result: Increased the number of apoptotic cell in time- and dose-dependent manner.
|
| In Vivo |
QN523 (10 and 20 mg/kg; i.p.; daily, for 44 d) inhibits tumor growth in mice of pancreatic cancer xenografts[1]. Animal Model: NOD/SCID mice of pancreatic cancer xenografts (6 weeks of age) Dosage: 10 and 20 mg/kg Administration: Intraperitoneal administration; 1-9 days (10 mg/kg), 10-44 days (20 mg/kg) Result: Delayed growth of the tumors, and no systemic toxicity.
|
| References |
[1]. Kuang Y, et, al. Induction of Genes Implicated in Stress Response and Autophagy by a Novel Quinolin-8-yl-nicotinamide QN523 in Pancreatic Cancer. J Med Chem. 2022 Apr 28;65(8):6133-6156.
|
